Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Knight Therapeutics Inc banner
K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.9 CAD 0.51%
Market Cap: CA$585.8m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

GUD Price Targets Summary
Knight Therapeutics Inc

Wall Street analysts forecast GUD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GUD is 8.09 CAD with a low forecast of 6.21 CAD and a high forecast of 10.5 CAD.

GUD Lowest Forecast
Wall Street Target
6.21 CAD
5% Upside
GUD Average Forecast
Wall Street Target
8.09 CAD
37% Upside
GUD Highest Forecast
Wall Street Target
10.5 CAD
78% Upside
Lowest
Price Target
6.21 CAD
5% Upside
Average
Price Target
8.09 CAD
37% Upside
Highest
Price Target
10.5 CAD
78% Upside
Knight Therapeutics Inc Competitors:
Price Targets
CADE
Cadence Bank
7% Upside
LE
Lands End Inc
102% Upside
CADE
Cadence Bank
7% Upside
LE
Lands End Inc
102% Upside

Revenue
Forecast

93% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
93% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

For the last 9 years the compound annual growth rate for Knight Therapeutics Inc's revenue is 93%. The projected CAGR for the next 4 years is 11%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
47% / Year
Estimated Growth
Estimates Accuracy
72%
Average Beat
N/A
Past Growth
47% / Year
Estimated Growth
Estimates Accuracy
72%
Average Beat

The compound annual growth rate of Knight Therapeutics Inc's operating income for the next 4 years is 47%.

What are analyst estimates?

Net Income
Forecast

-21% / Year
Past Growth
69% / Year
Estimated Growth
Estimates Accuracy
35%
Average Beat
-21% / Year
Past Growth
69% / Year
Estimated Growth
Estimates Accuracy
35%
Average Beat

For the last 9 years the compound annual growth rate for Knight Therapeutics Inc's net income is -21%. The projected CAGR for the next 4 years is 69%.

What are analyst estimates?

See Also

Summary
GUD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GUD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GUD stock valuation using valuation multiples.
Wall Street Estimates
GUD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GUD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GUD's stock price target?
Price Target
8.09 CAD

According to Wall Street analysts, the average 1-year price target for GUD is 8.09 CAD with a low forecast of 6.21 CAD and a high forecast of 10.5 CAD.

What is Knight Therapeutics Inc's Revenue forecast?
Projected CAGR
11%

For the last 9 years the compound annual growth rate for Knight Therapeutics Inc's revenue is 93%. The projected CAGR for the next 4 years is 11%.

What is Knight Therapeutics Inc's Operating Income forecast?
Projected CAGR
47%

The compound annual growth rate of Knight Therapeutics Inc's operating income for the next 4 years is 47%.

What is Knight Therapeutics Inc's Net Income forecast?
Projected CAGR
69%

For the last 9 years the compound annual growth rate for Knight Therapeutics Inc's net income is -21%. The projected CAGR for the next 4 years is 69%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 317,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.